On Friday, Lyell Immunopharma Inc (NASDAQ: LYEL) opened lower -6.54% from the last session, before settling in for the closing price of $0.43. Price fluctuations for LYEL have ranged from $0.39 to $2.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 332.01%. Company’s average yearly earnings per share was noted 43.61% at the time writing. With a float of $124.88 million, this company’s outstanding shares have now reached $294.88 million.
The extent of productivity of a business whose workforce counts for 300 workers is very important to gauge. In terms of profitability, gross margin is -24409.84%, operating margin of -591949.18%, and the pretax margin is -562285.25%.
Lyell Immunopharma Inc (LYEL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lyell Immunopharma Inc is 57.72%, while institutional ownership is 22.16%. The most recent insider transaction that took place on Mar 31 ’25, was worth 19,958. In this transaction Director of this company bought 35,640 shares at a rate of $0.56, taking the stock ownership to the 35,640 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Director bought 200,000 for $0.58, making the entire transaction worth $115,220. This insider now owns 200,000 shares in total.
Lyell Immunopharma Inc (LYEL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 43.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.29% during the next five years compared to -19.90% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Check out the current performance indicators for Lyell Immunopharma Inc (LYEL). In the past quarter, the stock posted a quick ratio of 7.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1968.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.31, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
The latest stats from [Lyell Immunopharma Inc, LYEL] show that its last 5-days average volume of 0.73 million was inferior to 0.93 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 18.76%. Additionally, its Average True Range was 0.05.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 2.56%, which indicates a significant decrease from 8.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.46% in the past 14 days, which was lower than the 85.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5198, while its 200-day Moving Average is $0.9030. Now, the first resistance to watch is $0.4307. This is followed by the second major resistance level at $0.4615. The third major resistance level sits at $0.4818. If the price goes on to break the first support level at $0.3796, it is likely to go to the next support level at $0.3593. Assuming the price breaks the second support level, the third support level stands at $0.3285.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
There are currently 295,338K shares outstanding in the company with a market cap of 118.14 million. Presently, the company’s annual sales total 60 K according to its annual income of -342,990 K. Last quarter, the company’s sales amounted to 10 K and its income totaled -191,940 K.
